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Metastasis is the leading cause of cancer deaths worldwide. However, there exist only very 
limited treatment options and they are often ineffective. An important aspect of metastasis that 
requires study, but has previously been understudied is circulating tumor cells (CTCs). CTCs are a 
critical step in the metastatic cascade. They can be analyzed for the identification of key 
mechanisms in metastasis. To this end, we isolated CTCs from a syngeneic mouse model of 
hepatocellular carcinoma (HCC) and a human xenograft mouse model of castration-resistant 
prostate cancer (CRPC). From these mouse models, primary tumor and CTC lines were 
established. Functional characterization of cells revealed CTCs to be more migratory than primary 
tumor cells. Additionally, CTCs underwent epithelial-to-mesenchymal transition (EMT) as 
observed through E-cadherin decrease and SLUG and fibronectin (FN1) increases. Taking 
advantage of the intact immune system present in the BALB/c syngeneic mouse model we used, 
we investigated the major histocompatibility complex class I (MHCI) cell surface molecule present 
on tumor cells and recognizable by cytotoxic T lymphocytes (CTLs). MHCI expression was 
decreased in CTCs. To investigate additional immune-evading mechanisms, CTC secretory profiles 
were examined. Endostatin, C-X-C motif chemokine 5 (CXCL5), and proliferin secretions were 
decreased in CTCs in comparison to primary tumor cells. Moreover, decreased intracellular 
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endostatin expression was found in CTCs. Taken together, our findings suggest that CTCs exhibit 
distinct characteristics from primary tumor cells.  Given that CTCs were more migratory and 
expressed higher levels of Fibronectin (FN1), SLUG, and Integrin B1 (ITGB1), we investigated FN1, 
SLUG, and ITGB1 relationship to CTC migration and one another. Knockdown studies of FN1, 
SLUG, and ITGB1 confirmed each to be important for CTC migration. Furthermore, FN1 was 
observed to regulate ITGB1 and SLUG. FN1’s regulation of these two molecules, however, 
involves two separate and independent pathways by which FN1 increases migration. Finally, we 
tested whether FN1 required ITGB1 and SLUG to exert its effects on CTC migration. We observed 
that while FN1 was able to induce migration, it required ITGB1 and SLUG to maximally enhance 
CTC migration. FN1 was previously mostly known for its role in being an extracellular matrix 
(ECM) protein, frequently overexpressed in cancers. Very little is known about FN1’s intracellular 
role and ability to regulate other molecules. This is the first time to our knowledge that FN1 is 
being reported to regulate ITGB1 and SLUG as a molecular mechanism for CTC migration. Further 
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 Metastasis is a multi-step process that results in the spread of cancer from one part of the 
body to another (see Figure 1.1) [1]. To date, it is responsible for over 90% of cancer-related 
mortalities worldwide [2, 3]. While present-day treatment options ameliorate symptoms and 
expand life by a few months, these medications remain ineffective at curing metastatic disease [4]. 
 Metastasis remains difficult to cure because there exists many gaps in knowledge in our 
current understanding of this advanced stage of disease. The molecular mechanisms dictating a 
cell’s ability to dissociate from the primary tumor, migrate and invade surrounding tissues until it 
reaches the circulation is not fully understood [2, 3, 5, 6]. Once in circulation, the question of how 
the immune system may be evaded when such cancer cells are in an environment rich with white 
blood cells, is also not completely understood [7, 8]. Moreover, further investigation is also needed 
to determine why and what factors prompt cancer cells to extravasate from circulation back into 
distantly located tissues. Finally, it is not known why metastatic cancer cells spread predominantly 
to certain parts of the body such as the lungs, bone, lymph nodes, brain or liver [3, 9]. Determining 
why certain parts of the body make for a more amenable environment to colonize by cancer cells 
is also a question worthy of further attention. 
 Fortunately, new technologies have emerged that are currently being developed and 
enabling the study of cancer metastasis. The conceptualization and development of liquid biopsies 
is one such example. The use of circulating tumor cells (CTCs) will be discussed in great length 
throughout this thesis because it is the manner by which we hope to elucidate mechanisms of action 
important for metastasis to occur [10, 11]. A noteworthy advantage in the use of CTCs is the ability 
to study metastatic mechanisms, without requiring invasive tissue biopsies. This is especially 
advantageous in cases where the secondary tumors are unable to be re-sectioned. It has been well 
established that metastasis could not occur without the detachment of CTCs from the primary 
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tumor. Therefore, through the use of these metastatic precursors or seeds of metastasis, CTCs 
obtained from the blood can help us better understand an otherwise elusive stage of disease [12]. 
 
 Figure 1.1: Metastasis is a multi-step process resulting in cancer spread. It begins with the 
 growth of the primary tumor. Angiogenesis, the creation of new blood vessels, helps feed 
 the primary tumor. This is followed by cancer dissemination resulting from cells migrating 
 and invading surrounding tissue. Cells then intravasate and enter the circulation, at which 
 point they are known as CTCs. Cells will travel to distant parts of the body until they reach 
 a point where they will extravasate out of the circulation back into tissue at a distant site. 
 The successful growth of cancer cells at secondary sites results in metastasis. 
 (Modified from Kim SJ et al 2009) 
 
1.2 Circulating tumor cells (CTCs) and their role in metastatic progression 
 CTCs are those cancer cells that have dissociated from the primary tumor and entered the 
circulation. They represent a critical step in the metastatic cascade [11, 13]. By elucidating novel 
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mechanisms of CTC action, our work has the potential to provide the scientific community with a 
better understanding of cancer metastasis.  
 Clinically, CTCs have been associated with a poorer prognosis in cancer patients [12]. As 
such, several leaders in the field are focusing on their use as a prognostic or diagnostic marker for 
the detection of cancer in asymptomatic patients. Still others are assessing CTCs in a patient’s 
blood to monitor the particular efficacy of a drug [13, 14]. While these are all further ways CTCs 
prove to be a valuable liquid biopsy resource, we will be using them to elucidate some of the 
molecular mechanisms permitting the spread of cancer to occur- particularly the migration and 
immunomodulation of CTCs. 
 It is important to note that CTCs are not the only type of liquid biopsy that has been used 
to study cancer. Research using liquid biopsies for cancer investigations has been steadily on the 
rise. Other types of liquid biopsies include circulating tumor DNA (ctDNA), exosomes, and 
circulating microRNAs (miRNAs) [15]. However, while each of these forms of liquid biopsies 
have their advantages, CTCs afford the unique ability to study the complete cellular and functional 
attributes of a cell transformed and on its way to form secondary metastatic lesions [11]. If we can 
characterize and investigate what makes these cells potentially more tumorigenic or prone to 
spreading, we can begin to better understand metastasis and not have it be an ultimate death 
sentence. 
1.3 Challenges in CTC research 
 Notwithstanding, there are several challenges that exist when using this precious resource. 
Most noteworthy are the very low amounts of CTCs found in the blood. In comparison to the 
millions of white blood cells (WBCs) and billions of red blood cells (RBCs) found in circulation, 
CTCs are found in amounts of 1- 5 cells/mL of blood [16-19]. To be able to harvest these rare 
cells, special devices have been developed. This coupled with single cell sequencing and other 
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similar single-cell profiling technologies have made it possible to circumvent low CTC counts and 
characterize these cells. However, such capture and enrichment technologies can be quite selective 
[14, 20]. Currently, the most popular, FDA-approved Cell Search system selects for CTCs on the 
basis if they originate from epithelial tissue, they will retain some of those epithelial characteristics 
while in circulation. Such a system isolates CTCs using a marker called Ep-CAM [21]. However, 
this system doesn’t account for the fact that some CTCS may have undergone an epithelial to 
mesenchymal transition (EMT), in which case these cells will not be selected for [22]. While other 
systems make use of size, impedence, or other cell surface marker differences between CTCs and 
surrounding blood cells, there still remains the issue of selectivity and thereby potentially not 
accounting for all the cells in a heterogenous CTC population. 
 Besides creating powerful tools to isolate and enrich CTCs, another way in which people 
have sought to molecularly characterize the limited CTCs found in blood is by creating CTC lines 
[23].  The advantage of expanding CTCs via this method is that one can study cell behavior and 
continue characterizing cell attributes in response to different treatments or genetic manipulations. 
This is an invaluable way to study these low occurring cells and understand how they promote 
metastasis [23]. However, the creation of long term CTC lines has been accomplished by only a 
select few [24-27]. We are among those, who have successfully been able to establish long term 
CTC lines, lasting more than 6 months and amenable to be made into stocks and put back into 
culture. In doing so, our goal was to use these newly created cell lines to functionally characterize 
CTCs and learn what makes them more metastatic than primary tumors. 
 
1.4 The establishment of novel CTC lines 
 While the idea of establishing long-term CTC lines seems enticing, the success rate of 
establishing such cell lines remains quite limited. Only several in the field have managed to make 
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short-term cell lines of CTCs, lasting several weeks to few months. This, when coupled with 
single-cell sequencing or other such technologies, has obtained invaluable information on the 
profiling of CTCs [28-37]. However, we are among the select few who have managed to create 
long-term CTC lines for continuous study in 2-D culture over greater than 6 months [24-27]. Of 
the three CTC lines established by our lab, two were from a syngeneic hepatocellular carcinoma 
(HCC) mouse model and one was from a human xenograft castration-resistant prostate cancer 
(CRPC) mouse model. From such models, we also derived primary tumor cell lines with which to 
compare our CTCs.  In doing so, we hoped to investigate the changes that CTCs undergo in 
comparison to primary tumors that enable them to be more metastatic. Our work therefore has the 
potential to shed light on the molecular mechanisms of metastasis by studying these rare cells 
expanded in culture. Our work demonstrates a methodology that can be used to successfully isolate 
and establish CTC lines of different tissue origins.  
 For this project, we chose to focus on two types of cancer that upon resulting in metastasis 
are seen as death sentences: HCC and CRPC [38]. HCC is the most common form of liver cancer. 
It is currently one of the leading causes of cancer death, worldwide [39-42]. Sorafenib, the only 
FDA-approved drug for advanced HCC, extends life by 6 months but patients eventually succumb 
to the disease [43]. Similarly, CRPC is an aggressive form of prostate cancer (PCa) that can 
develop in resistance to androgen deprivation therapy (ADT), the first line of therapy against PCa 
[44]. Over 90% of CRPC patients will develop bone metastasis over the course of the disease . 
While second generation ADT’s such as Abiraterone acetate and Enzalutamide, have proven to be 
of limited efficacy, there is evidence of patients developing secondary resistance and a more 
aggressive disease [45-47]. Because both cancers frequently advance, metastasize, and result in 
eventual patient death, we pursued these as our cancer models. 
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 The advantages of using different animal models of metastasis is that they also enabled us 
to take advantage of the distinct benefits offered by each model. The syngeneic mouse model of 
HCC permitted the study of CTC immunobiology. This is because in this model, the mouse from 
which our CTCs were derived from had a fully intact immune system [48, 49]. In contrast, the 
mice from our xenograft mouse model of CRPC, while immuno-compromised, permitted the study 
of a more human CRPC cancer model [50, 51]. We hypothesized that despite differences in tissue 
of origin, CTCs share inherent properties that enable their survival in the immunologically-
challenging blood environment, and enable them to be more metastatic-promoting. For this reason, 
we wished to molecularly and functionally characterize our new CTC lines and compare them with 
their corresponding or matched primary tumor cell lines.  
 
1.5 Functional and molecular characterization of CTCs 
 Several groups have made significant advances in characterizing CTCs. A number of 
researchers have performed genomic CTC profiling to identify mutations involved in cancer 
dissemination, as well as in response to therapeutic interventions or molecular manipulations [11]. 
Our work seeks to combine both functional assays and molecular characterization of CTCs to 
uncover potential mechanisms driving metastatic spread. As defined by Douglass Hanahan and 
Robert Weinberg, there are several biological capabilities acquired by cells when they develop 
into neoplastic lesions. The two hallmarks we have focused on is migration & metastasis, as well 
as avoidance of immune destruction [52]. Both are currently understudied mechanisms in CTC 




1.6 Investigating molecular mechanisms of CTC migration for a better understanding of 
metastasis 
 
 Of particular interest and relevance to metastasis is migration. In order for neoplastic cells 
to be able to metastasize to other parts of the body, they need to gain the ability to migrate away 
from the primary tumor, invade tissues, and enter the circulation where they are transported to 
other parts of the body. Metastasis, therefore, cannot occur without migration-enabling 
mechanisms [9]. Interestingly, our results show all three CTC lines demonstrate greater migration 
than their corresponding primary tumor cell lines. We also identify several molecules with 
previously known migration roles to be upregulated in our CTCs: fibronectin (FN1), integrin beta 
1 (ITGB1), and SLUG (SNAI2). Given that all three of these molecules were significantly 
upregulated in the CTC lines, we sought to investigate whether they were related to one another. 
We also wanted to see if they were necessary for CTC migration to occur. Currently, the complex 
mechanisms regulating CTC migration are not completely understood. 
 
1.7 Current knowledge of Fibronectin (FN1), Integrin B1 (ITGB1), and SLUG and their 
effects on cell migration  
 FN1 is mostly known for its role as a critical player in the extracellular matrix (ECM). It 
is a multifaceted glycoprotein that binds to various constituents of the ECM, as well as receptors 
found on a cell’s surface. As such, it mediates the cross-talk between cells and their external 
environment [53]. Currently, the focus has shifted from FN1 to investigating the integrin receptors 
to which they bind to affect various cell processes, including cell migration which we will be 
focusing on. We hypothesize that FN1 may have more pro-active regulatory roles dictating CTC 
migration which has previously not been shown. Interestingly, FN1 has been observed to be 
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upregulated in a variety of cancers, and associated with a poorer clinical outcome[53-56]. In CTCs, 
a higher FN1 molecular profiling has been used as an indicator of CTCs obtaining a more 
mesenchymal state. However, we are the first to report FN1’s regulation of ITGB1, an integrin 
receptor subunit, and SLUG, a transcription factor enabling EMT. 
 Integrins are the receptors most commonly bound to by FN1. These receptors are made of 
18 possible alpha- and 8 possible beta- subunits. Of these, ITGB1 is  considered to be the most 
abundant subunit [57]. Most importantly, ITGB1 has been reported to be increased in several 
cancers and has been linked with the regulation of cell motility. Likewise, SLUG, also known as 
SNAI2, is a critical transcriptional regulator of a process known as EMT which enables migration 
to occur. SLUG is a member of the SNAIL zinc finger family of transcriptional repressors. While 
it is known that SLUG binds to and represses E-cadherin for the induction of a more mesenchymal 
phenotype, plenty is still unknown about this molecule [58-61]. Our work seeks to shed light into 
the manner by which FN1 may be regulating both of these molecules to contribute to metastatic 
and migratory mechanisms of CTCs. 
 
1.8 Summary and Project Rationale 
 
The aim of our research was to study CTC biology in order to better understand several important 
molecular mechanisms that may be previously unknown and may have important implications for 
cancer metastasis. In particular, we have studied CTC migration because our data progressively 
implicated CTC migration as an important aspect of CTC biology that is different from primary 
tumor cells. As a result, for the first time we shed some light as to how greater intracellular FN1 
expression may be promoting enhanced CTC migration. Furthermore, we were interested in 
investigating immuno-modulating mechanisms of CTCs and therefore assessed expression of 
 10 
major histocompatibility complex I (MHCI), an important molecule that enables T cells to 
recognize cancer cells. In addition, we also assessed the immuno-secretory profile of CTCs in 
comparison to primary tumor cells because this is a mechanism they could potentially use to 
dampen the immune response. Our results have interesting implications for how CTCs may evade 
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2.1 Mouse tumor studies 
 
 
For the syngeneic mouse model of HCC, 7-week old, male, BALB/c mice were obtained from 
Taconic Biosciences Inc. Mice were implanted with 2.5 × 106 BNL 1ME A 7R.1 murine HCC 
cells. For the NOD scid gamma (NSG) human xenograft mouse model, 7-week old, male NSG 
mice were obtained from Jackson Laboratory. Mice were implanted with 2.5 × 106 22Rv1 human 
CRPC cells. Tumors were allowed to grow until reaching a max tumor volume of 2000 cm3, at 
which point mice were euthanized, tumors removed, and samples of blood processed for CTCs as 
previously described by our lab [62]. Briefly, up to 1 mL of blood was obtained from intracardiac 
blood withdrawal from mice. The blood was spun down and the plasma removed. The rest of the 
blood sample, most importantly the buffy coat layer, which is where we expect our CTCs to be, 
was treated with red blood cell lysis buffer. After a series of spins and washes, samples were placed 
in media. Experiments on CTC cell lines were carried out for as long as forty-five passages (well 
over 6 months). Features remained consistent among different passages. While efficiency of cell 
line establishment was moderate to low, once established, the CTC cell lines exhibited high cell 
viability. In terms of our primary tumor cell lines, tumors were mechanically dissociated in media 
and given the chance to adhere to the plate to give rise to primary cell culture cell lines. H&E 
staining was performed to confirm metastasis to lungs using the core facilities at Albert Einstein 
School of Medicine. All mouse experiments were performed in compliance with Institutional 
Animal Care and Use Committee (IACUC)–approved protocols at Weill Cornell Medicine. 
 
2.2 Tissue processing and histology 
 
 
        From each mouse, tumors and lungs were excised, fixed in 4% paraformaldehyde, immersed 
in 30% sucrose in 1x PBS solution, and made into cryomolds using a 1:2 ratio of 30% sucrose in 
PBS in O.C.T (Optimum Cutting Temperature) tissue freezing media. Frozen cryomolds were then 
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delivered to our collaborators at Albert Einstein School of Medicine. H&E histological staining of 
cryomold tissue samples was performed by expert trained pathologists at Albert Einstein’s core 
facilities. 
 
2.3 Cells and cell culture conditions 
 
 
The BNL 1ME A 7R.1 cell line (purchased from ATCC), as well as the newly created primary 
tumor cell lines (TBOH1 and -9) and circulating tumor cell lines (CBOH4 and -9), were maintained 
in Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
1% Penicillin/Streptomycin, and L-glutamine. Trypsinization of cells occurred using 0.25% 
trypsin when cells reached 75-80% confluency. 
The 22RV1 cell line (purchased from ATCC), as well as the newly created primary tumor cell 
line T22OH and circulating tumor cell line C22OH, were maintained in Roswell Park Memorial 
Institute (RPMI) 1640 media supplemented with 10% FBS and 1% penicillin/streptomycin. 
Trypsinization of cells occurred using 0.05% trypsin when cells reached 75-80% confluency. All 
cells, of both HCC and CRPC origin, were kept in a 5% CO2 and 37°C incubator.  
 
2.4 Immunofluorescence staining 
 
 
Cells were incubated with coverslips and grown for 48hrs. Coverslips were collected, fixed 
with 4% Paraformaldehyde for 15 min at room temperature, permeabilized with 0.5% Triton X-
100 in PBS/1% FBS for 10 min at room temperature. Cells were stained with CREB3L3 antibody: 
sc-377331 (1:500; Santa Cruz Biotechnology, TX, USA)  or Endostatin antibody: PA1-601 (1:200; 
Thermo Fisher Scientific, Rockford, IL, USA) for 2 hrs, followed by incubation with Alexa Fluor 
635 anti-rabbit 2°antibody: A31577 (Thermo Fisher Scientific, Rockford, IL, USA) for 1 hr. DAPI 
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was used to counterstain nuclei and slides were imaged using Nikon A1 confocal microscope at a 
60x magnification. 
 
2.5 Protein extraction and western blotting 
 
 
Whole cell extracts were obtained by treating cells with RIPA lysis buffer (Amresco, Ohio, 
USA, cat#: N653), supplemented with 10X protease inhibitors (Thermo Fisher Scientific, 
Rockford, IL, USA, cat#: 88665) and 100mM PMSF (Amresco, OH, USA, cat#: M145). Protein 
concentration was calculated via the Bradford Assay using the BIORAD Protein Assay Dye 
Reagent Concentrate. For Western blot analysis, 30ug of protein were run on precast SDS-PAGE 
gels, and subsequently transferred onto nitrocellulose membranes. Membranes were blocked in 
5% BSA in TBS-T for 1 hour at room temperature, incubated with primary antibodies overnight 
at 4°C, washed with 1x TBS-T, incubated with secondary antibodies for 1 hour, washed, and 
imaged using the LI-COR Odyssey CLx imager with infrared fluorescence. Primary antibodies 
used were against Fibronectin: ab2413 (1:1000; Abcam, Cambridge, UK), E-Cadherin: 3195S 
(1:200; Cell Signaling, MA, USA), CREB3L3: sc-377331 (1:500; Santa Cruz Biotechnology, TX, 
USA), AR-V7: ab198394 (1:1000; Abcam, Cambridge, UK), PSA: sc-7316 (1:200; Santa Cruz 
Biotechnology, TX, USA), Integrin B1: 4706S (1:500; Cell Signaling, MA, USA), SLUG: 9585S 
(1:500; Cell Signaling, MA, USA), GAPDH: 5174S (1:1000; Cell Signaling, MA, USA), Alpha-
tubulin: sc-32293 (1:500; Santa Cruz Biotechnology, TX, USA), and Beta-Actin: A5441 (1:5000; 
Sigma, St.Louis, MO, USA). Secondary antibodies used included anti-mouse: 925-32210 
(1:15,000; LI-COR, Lincoln, NE, USA) and anti-rabbit: 925-32211 (1:15,000; LI-COR, Lincoln, 






2.6 RNA extraction and quantitative real-time polymerase chain reaction (qPCR) 
 
 
RNeasy Mini Kit (QIAGEN, Hilden Germany, cat#: 74104) was used to isolate total RNA 
from each of the cell lines used in this study, according to the protocol specified by the 
manufacturer. RNA concentration was measured using the spectrophotometer NanoDropTM 2000 
(Thermo Fisher Scientific, Inc.) cDNA was obtained using 1ug of RNA and the QuantiTect 
Reverse Transcription kit (QIAGEN, Hilden, Germany, cat#: 205311).  
Expression of SLUG was measured by quantitative real time qPCR using SYBR-Green 
Master mix (Life Technologies, CA, USA, cat#: 4309155). Primers for SLUG and GAPDH were 
created with the OligoPerfect Designer program (ThermoFisher Scientific Inc; Wilmington, DE, 
U.S.A).    The following oligonucleotide sequences were used for primers: murine SLUG-F, 5’-
CCTTTCTCTTGCCCTCACTG-3’ and murine SLUG-R, 5’-ACAGCAGCCAGACTCCTCAT-
3’; murine GAPDH-F, 5’-TGATGGGTGTGAACCACGAG-3’ and GAPDH-R, 5’-
AGTGATGGCATGGACTGTGG-3’; human SLUG-F, 5’-CTTTTTCTTGCCCTCACTGC-3’ 
and human SLUG-R, 5’-GCTTCGGAGTGAAGAAATGC-3’; human GAPDH-F, 5’-
GAGTCAACGGATTTGGTCGT-3’ and human GAPDH-R, 5’-
TTGATTTTGGAGGGATCTCG-3’. For each sample, SLUG was normalized with GAPDH 
expression.  The comparative cycle threshold (Ct) method was used to quantify relative target gene 
expression.  The instrumentation used to perform qPCR is Quantifect Studio System (Applied 
Biosystems).  
 
2.7 Wound healing migration assays 
 
 
For wound-healing assays, 5 x 104 cells were grown in a 6-well tissue culture plate and 
permitted to reach 90-100% confluency. Using a plastic tip (1mm thick), wounds were 
administered to monolayers of cells in each well. Wounded monolayers were washed with 1xPBS 
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and incubated with media. Cells were observed and images taken using the Motic AE30 Inverted 
Microscope. The time for wound closure was measured. Experiment was stopped when at least 
one condition showed complete wound closure. 
 
2.8 Transwell migration assays 
 
 
For transwell migration assays, 1 x 105 cells were seeded on the top of chambers containing 
8um pores (Greiner Bio-one, Austria, cat #: 662 638) in serum-free media. Bottom chambers were 
filled with regular media to serve as a chemoattractant. After 48 hrs, top chambers were rinsed 
with 1x PBS, fixed with paraformaldehyde, treated with methanol, and stained with trypan blue 
staining. Chambers were placed on a slide and viewed using the Motic AE30 Inverted Microscope. 
All migration assays were carried out at least 3 times.  
 
2.9 Transfection of siRNAs 
 
 
Cells were grown in 6-well plates. When reaching a confluency of 60-70%, cells were transfected 
according to the manufacturer’s instructions using Lipofectamine. Briefly, cells were transfected 
with 10nM of either Fibronectin siRNA (Santa Cruz Biotechnology, TX, USA, cat#: sc-29315), 
IntegrinB1 siRNA (Santa Cruz Biotechnology, TX, USA, cat#: sc-35674), SLUG si RNA (Santa 
Cruz Biotechnology, TX, USA, cat#: sc-38393), or a non-targeting Scramble siRNA control 
(Sigma, St.Louis, MO, USA), using Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc; 
Wilmington, DE, USA) diluted in Opti-MEM (ThermoFisher Scientific Inc; Wilmington, DE, 
U.S.A). The final concentration of siRNAs in lipofectamine solution used to treat cells was 
25pmol. Cells were allowed to incubate for 12-24 hours at 37°C, until either migration assay was 




2.10 Treatment of cells with recombinant protein 
 
 
       Cells were seeded in 6-well plates. Upon reaching 60-70% confluency, cells were treated with 
Recombinant Fibronectin (R&D Systems, Minneapolis, MN, USA). Final concentration of 
recombinant protein per well was 2ug/ml. Cells were incubated for 12-24 hrs at 37°C until either 
migration assay was finished, or cells were collected for extracting protein and running on a gel. 
 
2.11 Flow Cytometry 
 
 
Cells were incubated with trypsin for 3 minutes in order to harvest them. Pellets were washed, 
spun at 1,200 rpm for 5 min, and re-suspended in 1% BSA in 1x PBS incubation buffer. Cells were 
spun and treated with mouse Fc block (BD Biosciences, NJ, USA, cat#: 553142) for 20 minutes. 
Either FITC anti-mouse MHCI antibody (BD Biosciences, NJ, USA, cat#: 553565) or its 
corresponding FITC Mouse Isotype control (BD Biosciences, NJ, USA, cat#: 553456) was added 
to cells and allowed to incubate for 1 hour. Samples were fixed with 2% Paraformaldehyde for 30 
min at 4°C, washed, and re-suspended in 1x PBS. Analysis was done using the BD FACs 
instrumentation and software version 7.0 (BD Biosciences, NJ, USA).  
 
2.12 Cytokine array studies 
 
 
TBOH and CBOH cell lines were screened simultaneously for 111 murine cytokines using 
the Mouse XL Cytokine Array (R&D Biosystems, MN, USA, cat#: ARY028). Duplicate 
experiments were performed according to the manufacturer’s instructions. Media in which cells 
were cultured for 2 days after being passaged was collected and used to assess cytokine secretions. 
Membranes with 111 spotted targets in duplicate were immersed in 1 ml of collected media + 
0.5ml of Buffer 4/6 from kit and allowed to incubate overnight at 4°C. After a series of washes, 
membranes were further incubated for 1 hour in diluted Detection Antibody Cocktail, washed, 
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treated with 1x Streptavidin-HRP for 30 minutes, further washed, and finally treated with Chemi 
Reagent Mix. Membranes were placed in sheet protectors and placed face-up in an 
autoradiography film cassette. In the dark, membranes were exposed to membranes for 1-10 
minutes. Cytokine signals were quantified with densitometry using Image J software.   
 
2.13 Statistical Analyses 
 
 
Data from at least 3 different independent experiments were collected and presented as mean 
+ standard error (SEM) of the mean. Statistical significance was evaluated using Student’s t test. 
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Metastasis results in 90% of cancer deaths worldwide [2]. It occurs in a series of steps, which 
include the dissociation of cells from the primary tumor, migration through surrounding tissue, 
intravasation, circulation through blood, followed by extravasation and re-colonization of distant 
sites throughout the body. Currently, there are limited treatment options for this advanced stage of 
disease [2, 4, 5]. As a result, efforts are increasingly being focused on identifying novel metastatic 
molecular targets. 
Circulating tumor cells (CTCs) presents a non-invasive way to study metastasis. CTCs are 
cells which have dissociated from the primary tumor and are found traveling in the blood [12-15, 
63]. Some CTCs will eventually form metastatic, secondary lesions. Unfortunately, they are found 
in low counts within the blood. To circumvent this problem, we have established novel CTC lines 
and matched primary tumor cell lines for investigation and identification of metastatic-promoting 
molecular mechanisms.  
The cancers we chose to focus on were HCC and CRPC- both which frequently result in overt 
metastasis. HCC is the most common form of liver cancer and one of the leading causes of cancer 
deaths, worldwide [38, 40, 41, 64]. Moreover, sorafenib, which is the main FDA approved drug to 
treat advanced HCC, extends life by only six months [43]. As such, better treatment options are 
needed. Similarly, CRPC is a form of prostate cancer (PCa) that is resistant to androgen deprivation 
therapies (ADT) such as medical and surgical castration [45, 47]. Resistance towards ADTs makes 
CRPC particularly challenging to treat. Over one third of CRPC patients will develop bone 
metastasis for which there is no cure [45, 65]. Therefore, understanding how metastasis is driven 
in CRPC is critical for developing alternative treatments for advanced diseases. 
To this end, we propagated novel primary tumor cell lines and CTC lines from our syngeneic 
mouse model of HCC and xenograft mouse model of CRPC. Our aim was to discover differences 
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between these two cell types representing earlier and more advanced stages of cancers. Both HCC 
and CRPC CTCs demonstrate increased migration and evidence of epithelial-to-mesenchymal 
transition (EMT). Moreover, we identified differences in CTC cell surface marker profiles for 
MHCI that could have immunomodulatory implications. HCC CTCs had significantly reduced 
major histocompatibility complex class I (MHCI) expression, as compared to primary tumor-
derived cells. These findings may have implications for the function of metastatic cells and how 






3.2.1 – The establishment of new primary tumor and CTC lines 
 
 For the syngeneic mouse model of HCC, we implanted BALB/c mice with BNL 1ME A 
7R.1 murine HCC cells. For our xenograft mouse model of CRPC, we implanted NSG mice with 
22Rv1 human CRPC cells. Upon mice euthanasia, tumors from mice were resected, mechanically 
dissociated, and made into primary tumor cell lines. To obtain CTC lines, intracardiac blood 
withdrawal was performed on mice. Collected blood was spun down, plasma removed, and 
remaining blood samples were treated with RBC lysis buffer. After a series of spins and washes, 
samples were placed in media. After a number of passages, remaining WBCs would have died off 
and resulted in a pure population of CTCs in culture. The aforementioned methodology and 
resulting cell lines are summarized in Figure 3.1 
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Figure 3.1: Establishment of novel primary tumor and circulating tumor cell lines. A) 
Schematic diagram showing how novel cell lines were obtained. This figure has been adapted from 
[66] and developed further by [62]. Briefly, upon implantation, cancer cells took up to 1 month to 
form primary tumors. Mice were sacrificed before primary tumors reached a final tumor volume 
of 2000cm3. Up to 1ml of blood was collected from intracardiac blood withdrawal. Blood samples 
were subjected to red blood cell (RBC) lysis and any remaining white blood cells (WBCs) were 
removed by loss of viability and washes after a number of passages leaving behind CTCs in 
culture. B) The newly established cell lines. TBOH1 and CBOH4 were the first pair of primary 
tumor and CTC lines, followed by TBOH9 and CBOH9 for our HCC model. T22OH and C22OH 
were the single pair of primary tumor and CTC lines for our CRPC model. 
 
 
3.2.2 - CTCs obtained from blood demonstrate tissue specific markers 
 
After establishment of novel CTC lines, we confirmed their appropriate tissue specificity. To 
confirm that CTCs obtained from the blood of syngeneic HCC mouse models were of liver origin, 
we performed immunofluorescence staining for CREB3L3, a validated liver specific marker [67, 
68]. As expected, the primary tumor cell lines TBOH1 and TBOH9 demonstrated strong 
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CREB3L3 expression as shown by the red pigmentation in cells in Figure 3.2 A,C. Similarly, the 
CTCs CBOH4 and CBOH9 also showed distinct CREB3L3 expression, confirming their liver 
origin, as well as their derivation from TBOH1 and TBOH9, respectively. No signal was observed 
in the negative controls in which cells were incubated with only secondary antibody. Western 
blotting also revealed the presence of CREB3L3 for both CBOH4 and CBOH9, as seen in Figure 
3.2 B,D. 
Similarly, to confirm that the cells obtained from the blood of xenograft CRPC mice were of 
prostate origin, we performed western blotting for prostate specific antigen (PSA) and the 
androgen receptor variant 7 (AR-V7). PSA is a protein produced by prostate cells. Moreover, AR-
V7 is a spliced variant form of the androgen receptor that is present on the parental cell line 22Rv1 
[69-71], which was implanted subcutaneously into mice to form CRPC tumors. Both T22OH and 
C22OH demonstrated distinct PSA and AR-V7 expression as shown in Figure 3.2 F, confirming 
their origin from the prostate, as well as their derivation from the human CRPC parental cell line, 
22Rv1.  
 
3.2.3 - CTCs were obtained from mice with metastatic lesions 
 
In addition to showing that CTCs were hepatic-specific, we also performed H&E staining on 
lung tissues obtained from mice from which HCC cell lines were obtained. This was to confirm 
the occurrence of metastasis to the lungs, as shown in Figure 3.2 E by pigmentation and irregular 
morphology of lung tissue in HCC-implanted mice in comparison to lung tissue of non-cancer 
bearing mice.  
Furthermore, metastasis was also confirmed to have occurred in our xenograft mice model of 
CRPC upon mice necropsy. Multiple macroscopic tumors were observed throughout the entire 
animal, as expected from this highly metastatic cancer. 
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As a result, we confirm the isolation of CTCs from the blood from our syngeneic HCC and 
xenograft CRPC mouse models. To determine differences between CTCs and their corresponding 
primary tumors, functional assays were performed measuring several hallmarks of cancer. 
 
 
Figure 3.2: CTCs obtained from the blood demonstrate tissue specific markers and 
were derived from mice exhibiting metastasis. A, C) Immunofluorescence staining 
probing for CREB3L3- a liver specific marker- in HCC cell lines. DAPI nuclear staining 
is shown in blue; cytoplasmic CREB3L3 staining is shown in red. Scale bars, 20um. B, D) 
Western blotting for CREB3L3 displays a distinct positive signal for all HCC cell lines. E) 
H&E staining reveals mice, from which CTCs were obtained, had metastasis to the lungs, 
as noted by evidence of neoplasia observed in the lungs of cancer-afflicted mice. F) 
Western blotting was carried out to confirm prostate cancer origin for both CRPC-derived 
cell lines. Positive signals for ARV7 and PSA were observed for primary tumor cells and 
CTCs. Experiments were carried out 3 times.  
 
3.2.4 – CTCs are significantly more migratory than primary tumors 
 
Cancer cell migration is required for cancer metastasis [3, 9]. To assess the migratory 
capability of both primary tumor-derived and CTC HCC cells, we performed wound healing 
migration assays. The rate at which wounds closed determined the migratory capability of cells. 
As shown in Figure 3.3 A, C, we observed that CTCs (CBOH4 and CBOH9) were more migratory 
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than their corresponding primary tumor-derived cell lines (TBOH1 and TBOH9, respectively). 
CBOH4 displayed a 55% increase in migration in comparison with TBOH1 (Figure 3.3 B). 
Likewise, CBOH9 demonstrated ~30% greater migration in comparison to TBOH9 (Figure 3.3 
D). The increased migration of CTCs in comparison with their corresponding primary tumors is 
statistically significant. 
To analyze the migratory capability of CRPC cells, we performed transwell migration assays. 
Cells were fixed, permeabilized, and stained. The number of cells passing through the transwell 
chamber pores determined the migratory capability of cells. As shown in Figure 3.3 E–F, the 
C220H CTC line demonstrated a four-fold increase in migration in comparison to the primary 
tumor cell line T22OH. 
 
 Figure 3.3: CTCs exhibit greater migration than cancer cells from primary tumors. 
 A and C) Wound healing migration assays were performed on HCC cell lines. Cells were 
 grown in 6 well plates. When confluent, wounds were made and measured at 0 and 9 hr 
 intervals. CTCs had completely closed by 9 hours, demonstrating faster migration. Wound 
 area was measured using Motic Images Plus 2.0 software. B and D) Migration was 
 quantified from 3 independent experiments.  E) Transwell migration assay was performed 
 26 
 for CRPC cell lines. 50,000 cells were seeded inside a transwell chamber containing serum-
 free media for 24 hrs. Cells which migrated successfully through the transwell chamber 
 membrane were fixed and stained with trypan blue. F) Migration was quantified from 3 
 independent experiments. Data provided on graphs are presented as mean ± the standard 
 error of the mean (SEM).  
 
 
3.2.5 – CTCs exhibit an epithelial to mesenchymal transition (EMT) 
 
Having observed greater migration from CTCs in comparison to primary tumor cells, we 
wanted to determine whether CTCs were undergoing EMT. This is a phenomenon frequently 
observed in cancer cells that gain the capacity to migrate and metastasize [72-77]. Using western 
blotting, we examined protein expression of fibronectin, a well-known marker of migratory and 
mesenchymal cells [53-56, 78]. As observed in Figure 3.4 A–C, CTCs had greater fibronectin 
protein expression in all three CTC lines. When quantified using Image J densitometry software, 
CBOH4 showed a 4.81-fold increase in fibronectin expression when compared to TBOH1; 
CBOH9 exhibited a 3.95-fold increase in fibronectin expression when compared with TBOH9. 
Finally, C22OH had a 3.52-fold increase in fibronectin expression in comparison with T22OH. 
The assessment of EMT is performed by observing several markers. To determine whether EMT 
occurred, we also looked at E-cadherin, a well-known cell adhesion protein characteristic of 
epithelial cells [79, 80]. E-cadherin expression was decreased 11.1-fold in CBOH4 in comparison 
to TBOH1; decreased 5.5-fold in CBOH9 in comparison with TBOH9, and decreased 2.1-fold in 
C22OH in comparison with T22OH.  
 EMT is also made possible by several transcription factors that initiate and maintain it [81]. 
One such transcription factor observed to be overexpressed in all three CTC cell lines was SLUG. 
The mRNA expression of this EMT transcription factor was assessed using qPCR. As shown in 
Figure 3.4 D, CBOH4 exhibited a 4.6-fold increase in SLUG mRNA expression in comparison 
with TBOH1. CBOH9 demonstrated an 11.1-fold increase in SLUG expression in comparison to 
the corresponding primary tumor cell line, TBOH9. Finally, C22OH exhibited a 1.5-fold increase 
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in SLUG mRNA expression in comparison to the T22OH cell line. These findings demonstrate 





 Figure 3.4: CTCs undergo epithelial-to-mesenchymal transition (EMT) as observed 
 through increased fibronectin, decreased E-cadherin, and increased SLUG. A and B) 
 Western blot was performed, probing for fibronectin and E-Cadherin in HCC cells, using 
 30ug of whole cell lysates. C) Western blot was also performed probing for fibronectin and 
 E-cadherin in CRPC cells, using 30ug of whole cell lysates. Western blotting in each case 
 was performed 3 separate times to confirm observations. D) SLUG mRNA expression was 
 assessed via qPCR for all cells. SLUG expression was normalized against GAPDH. Data 
 provided on graphs are presented as mean ± the standard error of the mean (SEM). N=3 
 
 
3.2.6 – CTCs show a decrease in MHCI cell surface expression 
 
To investigate potential immunomodulatory properties of CTCs, we used cell lines 
derived from the syngeneic HCC mouse model. Using flow cytometry, we assayed for 
MHCI, a well-established cell surface molecule involved in self-recognition or 
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identification of harmful entities and subsequent destruction by T-cells [82, 83]. As shown 
in Figure 3.5 A.B, we observed a 1.8-fold (45%) decrease in MHCI expression in the 
CBOH4 CTC line in comparison to the primary-tumor TBOH1 cell line. Similarly, as 
shown in Figure 3.5 C.D, we observed a 1.5-fold (35%) decrease in MHCI expression in 





Figure 3.5: HCC CTCs exhibit a downregulation in MHCI expression. A, C) MHCI 
cell surface expression was assessed via flow cytometry for all HCC cell lines. 100,000 
cells were used per sample for MHCI assessment. CTCs display decreased MHCI cell 
surface protein expression in comparison to primary tumor cell lines. Both isotype and 
MHCI antibodies were conjugated to FITC. Isotype, measuring background, is shown in 
red. MHCI signal is shown in green. B, D) MHCI cell surface expression was assessed 





Metastasis is the most common cause of death among cancer patients. Molecular mechanisms 
of cancer metastasis are not yet clear [2-6]. CTCs are an important step in the metastatic process. 
Consequently, we have focused on elucidating the molecular mechanisms of CTCs.  
However, CTCs are challenging to obtain in the human clinical setting [16-19]. To address 
these limitations, we have established an effective method for isolating and creating long-term 
cultures of CTC lines. The challenge involved in this task is underscored by the fact that only a 
few other groups have had success in doing this [24-27]. So far, it has been easier to establish short 
term CTC cultures, which when coupled with single-cell sequencing or short-term biochemical 
assays, have resulted in very useful information [28-37]. Furthermore, these techniques can be 
physically intensive and expensive. Here, we have described an approach for propagating CTC 
lines and using them for functional characterization, identification of novel pathways important 
for metastasis, and to gain insight into molecules that might have immunomodulatory implications 
in CTCs. 
In this work, we have focused on the use of HCC and CRPC models because they both have 
significant negative clinical outcomes. At present, there is no effective treatment for advanced 
HCC [38, 40, 41, 43]. Similarly, metastatic CRPC currently has no cure [44-47, 69]. 
In the present study, we have successfully propagated three pairs of CTC lines. Interestingly, 
all CTCs demonstrated significantly greater migratory capacity than their primary tumor-derived 
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counterparts. Furthermore, we investigated the role of EMT in CTCs. EMT is a phenomenon that 
is frequently observed in cancer cells during cancer progression [72-74]. Accordingly, we 
observed evidence of EMT in CTCs as demonstrated by downregulation of E-cadherin and 
upregulation of fibronectin and SLUG expression. Together, our findings indicate that enhanced 
migratory capacity and EMT are important characteristic of all CTCs, regardless of tissue of origin.  
Another interesting and under-studied field in CTC immunobiology. Our knowledge of the 
interaction of cytotoxic T lymphocytes (CTLs) and CTCs is quite limited [8]. To this end, we 
investigated the major histocompatibility complex class I (MHCI) expression of both HCC CTC 
lines. Taking advantage of their origin from a fully intact immune system mouse model, we wanted 
to assess MHCI expression levels. MHCI is an important cell surface molecule that enables CTLs 
to distinguish between “self” vs. “non-self”. Upon recognition of harmful entities presented by 
MHCI, CTLs will attack these MHCI-presenting cells [82, 83]. We observed significant reduction 
of MHCI expression in CTCs. This has interesting implications on how CTCs may circumvent 
immuno-surveillance. While the mechanism of immune evasion by tumor cells has been well 
established, we are among the first who have investigated MHCI expression in CTCs. Further 
work is will be needed to follow up on these implications of CTC mechanisms of action. 
It is important to also note that while our work highlights a novel methodology and the creation 
of new cell lines to uncover possible mechanisms of cancer cell action, our cell lines were obtained 
from murine models. Others have previously isolated CTCs from human patients using 
microfluidic devices to assess molecular phenotype and drug sensitivity [24-27, 84]. We propose 
our methodology to contribute to the field by adding yet another way in which we can harness the 
information gained from studying CTCs.  
 In summary, we have described the establishment of novel primary tumor-derived cell lines 
and CTC lines created by our lab using a feasible new method with the main objective of 
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elucidating novel CTC molecular mechanisms. Functional and molecular characterization of all 
newly created cell lines demonstrate that EMT, enhanced migration, and decreased MHCI 
expression are consistently observed in CTCs. Taken together, our findings demonstrate a practical 
and reproducible new way to isolate CTCs and establish them into cell lines. Interestingly, we also 
show that despite having originated from different tissues of origin, CTCs may also share some 




























































INVESTIGATION OF IMMUNO-SECRETORY PROFILES OF 













 The successful establishment of our novel CTC lines and corresponding primary tumor cell 
lines enabled the functional and molecular characterization of each to gain insights into CTC 
biology. Interestingly, we observed a significant decrease in MHCI cell surface expression. MHCI 
is a molecule found on the surfaces of all cells that enable nearby cytotoxic T-cells to recognize 
harmful entities and destroy them [82, 85]. The lower expression of MHCI on CTCs in comparison 
to primary tumor cells seems to suggest a potential mechanism by which CTCs circumvent the 
immune system.  
 Besides evading detection by immune cells, another way cancer cells have been reported 
to circumvent destruction by the immune system is by secreting molecules that could potentially 
dampen the immune response [86]. We questioned whether CTCs could potentially be secreting 
molecules that could have roles in dampening the immune response while in transit through the 
blood. Taking advantage of the fact that our HCC CTCs arose from a syngeneic mouse model and 
therefore from a fully intact and non-immunocompromised mouse, we further explored CTC 
immunobiology. Collecting media from each cell line, we assayed for similar trends in cytokine 
secretions among both HCC CTC lines: CBOH4 and CBOH9. We compared them with 
corresponding primary tumor cell lines, TBOH1 and TBOH9, respectively. Of the 111 cytokines 
that were assayed, 3 were consistently and significantly downregulated in CTCs: endostatin, 
CXCL5, and proliferin.  
 Interested in uncovering mechanisms of action potentially used by CTCs regardless of 
tissue of origin, we further investigated expression of endostatin in CRPC CTCs. We reasoned that 
because endostatin is being secreted at lower levels by CTCs, endostatin must be expressed at 
lower levels intracellularly. Immunofluorescence was used to detect endostatin intracellular levels. 
In agreement with our cytokine array secretion results, intracellular expression of endostatin was 
 34 
significantly decreased throughout CTC cells. Most importantly, we observed this same trend to 
occur in CTCs of CRPC origin. In support of our hypothesis, these results have implications for 
ways CTCs may circumvent detection by the immune system, as well as hold some common 




4.2.1 – CTCs reveal lower secretion of endostatin, CXCL5, and proliferin 
Cytokines are secreted molecules that can activate signaling pathways and have effects on the 
immune response [87-89]. To determine if there are differences in the cytokine secretion profile 
between CTCs and primary tumor cells, a cytokine array was used. Of the 111 cytokines assayed, 
three were consistently and significantly lower in CTCs (see Figure 4.1A). Endostatin, an anti-
angiogenic molecule and inhibitor of tumor growth [90, 91], was decreased 2.27-fold in CTCs in 
comparison to primary tumor-derived cells (Figure 4.1B). CXCL5, a molecule that plays a role in 
attracting leukocytes such as neutrophils [92, 93], was also downregulated 2.38-fold in CTCs 
(Figure 4.1C). Finally, proliferin, a molecule with reported roles in cell growth regulation and 
differentiation [94-96], was decreased 1.28-fold in CTCs (Figure 4.1D). Statistical analyses found 
all three molecules to be significantly decreased, demonstrating p values of <0.05. 
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 Figure 4.1: HCC CTCs secrete lower levels of endostatin, CXCL5, and proliferin. Cytokine array 
 analysis of over 111 different secreted molecules was performed using cell media. Briefly-100,000 
 cells in  10ml of media were seeded in a T-75 flask. After 48 hours, 1ml of media was obtained for 
 incubation with cytokine array membranes. Detection was via biotin and streptavidin-HRP 
 antibodies using film. A) Representative images of decreased secretions of endostatin, CXCL5, and 
 proliferin by CTCs in comparison to primary tumors are shown. N = 2 (for each set of cell lines). B-
 D) Differential secretions of endostatin, CXCL5, and proliferin signals obtained from cytokine 
 array were quantified. Data provided on all graphs are presented as mean ± the standard error of 
 the mean (SEM). 
 
4.2.2 – CTCs reveal lower expressions of endostatin intracellularly  
 
Following up on the observation that CTCs secreted significantly reduced endostatin, we 
investigated intracellular endostatin expression in both of our HCC and CRPC CTCs using 
quantitative immunofluorescence. As shown in Figure 4.2A,B, CBOH4 had a 59% decrease in 
endostatin expression in comparison to TBOH1, and as shown in Figure 4.2C,D, CBOH9 had a 
48% decrease in endostatin expression compared to TBOH9. Furthermore, as seen in Figure 4.2 
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E, F, C22OH had a 40% decrease in the expression of endostatin in comparison to T22OH. Thus, 
we can conclude that CTCs from both HCC and CRPC models examined expressed significantly 
less intracellular endostatin than their corresponding primary tumor cells. 
 
Figure 4.2: CTCs demonstrate decrease in endostatin intracellular expression. Cells 
were grown on coverslips. A, C, E) Representative immunofluorescent images showing 
endostatin expression in A) TBOH1 and CBOH4, C) TBOH9 and CBOH9, and E) T22OH 
and C22OH. Microscope settings were held the same for both primary tumor and CTC 
lines. Scale bars, 20um. B, D, F) Mean fluorescence intensity was quantified using the NIS 
Elements Software. N=5 Data provided on all graphs are presented as mean ± the standard 






Taking further advantage of the CTC lines established by our lab in Chapter 3 and prompted 
by our previous findings that MHCI is interestingly downregulated in CTCs, we wished to 
elucidate other immunobiological mechanisms of CTCs. This is currently a field still growing and 
not completely understood [10, 11].  
CTCs are in constant communication with their surrounding tumor microenvironment. Upon 
dislodging from the primary tumor, traveling through tissues and entering the bloodstream, they 
are immersed in an environment rich with immune cells. Cancer cells have been very creative in 
the mechanisms by which they circumvent destruction by immune cells. Besides avoiding 
detection, another well recognized mechanism that has been reported but not studied fully in CTCs 
is via the secretion of molecules that may dampen the immune response or elicit the recruitment 
of immunosuppressive cells [7, 8]. To assess the immuno-secretory profile of CTCs, we used a 
cytokine array testing the presence of over 111 different molecular secretions found in the cell 
media of our cells. Here, we report for the first time that endostatin, CXCL5, and proliferin are 
secreted significantly less by CTCs than primary tumor-derived cells. Further studies are 
imperative to clarify the implications of this differential secretion profile of CTCs to cancer 
metastasis.  
Endostatin is known for its anti-angiogenic properties [90, 91, 97]. The fact that CTCs express 
less endostatin is intriguing and suggests that CTCs have acquired enhanced angiogenicity, which 
bodes well for the colonization of secondary sites. Moreover, it is conceivable that decreased 
endostatin secretion by CTCs may enhance their metastatic capability in other important ways [98-
100]. CXCL5 is a chemokine that recruits and activates neutrophils. While some studies associate 
higher CXCL5 expression with a worse cancer prognosis [92, 93, 101, 102], several reports 
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indicate that a lower CXCL5 expression can also promote metastatic spread [102-105]. Proliferin 
is a placental growth hormone that has been observed to be pro-angiogenic [94-96]. The 
implications of our current finding that CTCs secrete reduced amounts of proliferin than primary 
tumor-derived cells are currently unclear and deserve further study. It is noteworthy, however, that 
previous studies have found that as tumors grow in volume, intra-tumoral cells become hypoxic 
due to lack of oxygen within the tumor. This, in turn, stimulates the production of pro-angiogenic 
factors, enabling new blood vessel formation inside the tumor to deliver oxygen [106]. This 
process may not be necessary for CTCs, and may explain the observed reduced secretion of 
proliferin by CTCs.  
Interestingly, endostatin expression was found to be downregulated in all our CTCs regardless 
of tissue of origin. This was even more compelling since fibronectin, which was upregulated in 
our CTCs, has been previously reported to bind to the same integrin a5b1 receptor as does 
endostatin [107-112]. It is plausible that there could be a potential autocrine, competitive binding 
occurring between fibronectin and endostatin to the integrin a5b1 receptor with resulting 
implications in a cancer cell’s ability to migrate. Further studies are necessary to confirm or refute 
this idea.  
In summary, we have uncovered interesting and exciting observations implying ways CTCs 
may enhance their own tumorigenic properties. It is noteworthy to point out that while our intention 
for investigating CTC secretory profiles was driven by the belief that some of the molecules we 
would identify could have previously reported immuno-suppressive roles, this was not the case for 
all three newly identified differentially-secreted molecules. In fact, endostatin and proliferin have 
no previously reported role in immunomodulation. Furthermore whereas, endostatin has been 
noted to enhance the effectiveness of several immunotherapies [113, 114], its exact role in potential 
cancer immunobiology is unknown. It is interesting that all CTCs express lower levels of this 
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molecule, in comparison to primary tumors. However, for what purpose is still yet unclear. More 
curious is the fact that all three cytokines seem to have roles in angiogenesis- the growth of new 
blood vessels [96, 115-120]. As such, what began as an inquiry into the potential 
immunobiological mechanisms of CTCs may still reveal unknown roles of these molecules in 
directing CTC response to immune cells, but may also elucidate possibly new angiogenic or 
antiangiogenic CTC mechanisms, as well. To determine either of these possibilities, further 
experiments are required. Taken together, our findings demonstrate that CTCs have unique and 













































 The extracellular matrix (ECM), is a network rich in proteins and carbohydrates, that 
supports tissue structure, promotes cell communication, enables cell adhesion, as well as cell 
migration. During cancer progression, the ECM is subject to considerable alterations [121, 122]. 
Fibronectin (FN1) is a critical component and regulator of the ECM [123, 124]. Interestingly, FN1 
is overexpressed in a variety of cancers. Moreover, increased FN1 expression in tumor tissue has 
been linked to a poorer prognosis in cancer patients [125, 126]. Since its discovery in 1974, FN1 
has gained recognition for being a critical player in multiple aspects of cancer progression, 
including tumor cell migration, invasion, and metastasis [127-130].  
 A critical step in the metastatic cascade is the detachment of cancer cells from the primary 
tumor followed by their migration and subsequent intravasation into the bloodstream. These cells, 
known as CTCs can help us better understand critical aspects of the metastatic cascade [10]. It is, 
however, challenging to study CTCs as they are found in small numbers in the blood [16-19] . To 
address this challenge, we have expanded CTCs into cell lines. As previously reported in Chapter 
3, we successfully established 3 CTC lines: two from a syngeneic HCC mouse model and one from 
a xenograft CRPC mouse model. Both HCC and CRPC are examples of cancers that frequently 
advance to metastasis, are difficult to treat, and result in death [38, 39, 41, 42, 44, 46, 47, 131].  
 Functional characterization of our established cell lines revealed that CTCs display greater 
migration in comparison to primary tumor cells. Moreover, CTCs demonstrated increased FN1 
and SLUG expression, as observed in Chapter 3. In the present study, we also show that a 
prominent receptor sub-chain of FN1, called integrin beta 1 (ITGB1) [112], is also significantly 
overexpressed in CTCs. Because all three molecules have been observed by others to play a role 
in migration [129, 132, 133], we sought to determine whether the enhanced CTC migration we 
observed was due to increased FN1, ITGB1, and/or SLUG expression in these cells. Furthermore, 
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we investigated whether FN1’s enhancement of CTC migration requires ITGB1 and SLUG. 
Finally, we investigated whether FN1’s regulation of ITGB1 is upstream of SLUG, or whether 
FN1’s regulation of SLUG is upstream of ITGB1. Altogether, our study suggests two novel 
molecular mechanisms by which FN1 may regulate CTC migration, and further highlights the 





5.2.1 – Besides FN1 and SLUG, CTCs have increased ITGB1 receptor expression 
 
 Migration is essential for metastatic mechanisms to take place [9]. As such, our observation 
that CTCs established into cell lines demonstrated greater migration than their corresponding 
primary tumor cells was in accordance with our scientific expectations. Interestingly, intracellular 
FN1 was also increased in CTCs. One of FN1’s most well-known receptors are the integrins. 
Integrins are heterodimeric transmembrane receptors made of alpha and beta subunit chains [57, 
112, 134]. The beta 1 subunit chain, also known as integrin beta 1 (ITGB1) receptor, is the most 
abundant. It has been linked to poorer prognosis and increased tumorigenesis [132, 135]. To 
determine whether differences in ITGB1 expression existed, we performed western blotting to 
assess ITGB1 expression levels in CTCs and primary tumor cells. As observed in Figure 5.1 A-C, 
ITGB1 expression levels were elevated in all CTCs in comparison to primary tumor cells. 
 
 
 Figure 5.1: CTCs display increase in integrin B1 receptor (ITGB1) expression. 
 Representative western blot images of ITGB1 protein expression for all cell lines: A) 
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 TBOH1 and CBOH4, B) TBOH9 and CBOH9, and C) T22OH and C22OH. 30ug of protein 
 was loaded. Whole cell lysates were used. Alpha-tubulin served as a protein loading 
 control. Experiments were carried out 3 times. 
 
 
5.2.2 – FN1 is discovered to regulate ITGB1 and SLUG expression in CTCs  
Since CTCs expressed significantly greater FN1, ITGB1, and SLUG than primary tumor cells, 
we wished to investigate their possible relation to one another.  Interestingly, all three molecules 
have been implicated in cell migration [56-61, 128, 129, 134, 136-138]. Furthermore, the potential 
regulatory role of FN1 in CTCs has previously not been investigated, only FN1 serving as an EMT 
marker [77, 139-141]. To investigate FN1’s potential molecular mechanism of action and effects 
on ITGB1, we transfected CBOH4 and C22OH for 24 hours with either 25 pmol of FN1 siRNA 
or scramble siRNA. Interestingly, FN1 knockdown in CTCs resulted in a decrease in ITGB1 
protein expression (19.4% decrease in CBOH4 and 20.3% decrease in C22OH as seen in Figure 
5.2 A-B. To our knowledge, we are the first to report FN1’s regulation of ITGB1 in CTCs.                                                                                                                                                                                    
Like ITGB1, SLUG is also a molecule that has been associated with greater migration in 
cancer cells [58, 60, 61]. We therefore wanted to investigate whether FN1 may be regulating SLUG 
in CTCs. To determine the effect of FN1 knockdown on SLUG expression, we performed qPCR 
analysis. As shown in Figure 5.2 C, CBOH4 transfected with FN1siRNA demonstrated a 40% 
decrease in SLUG expression in comparison with CBOH4 transfected with scramble siRNA. 
Similarly, Figure 5.2 D shows that when C22OH is transfected with FN1 siRNA, cells 
demonstrated a 30% decrease in SLUG expression in comparison with cells transfected with 
scramble siRNA. We therefore conclude that FN1 has the capacity to regulate both ITGB1 and 
SLUG in CTCs to potentially enhance their migration. This was the main finding of our recently 
published paper [142]. 
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Figure 5.2: Fibronectin knockdown in CTCs induces a decrease in Integrin B1 and 
SLUG expression. A, B) After 24 hour transfection of CBOH4 and C22OH with 
sifibronectin, western blotting was performed to determine the potential effects on integrin 
B1 expression. Western blotting revealed that fibronectin knockdown in CTCs was 
successful. For HCC, CBOH4 transfected with sifibronectin was compared to those 
untransfected, transfected with siScramble, and TBOH1 primary tumor cell line. For 
CRPC, C22OH transfected with sifibronectin was compared to those transfected with 
siScramble and T22OH primary tumor cell line. Western blotting experiments were 
performed three separate times. C, D) Effect of fibronectin knockdown in CBOH4 and 
C22OH on SLUG expression was also assessed by qPCR. Expression was normalized 
against GAPDH. Data provided on graphs are presented as mean ± the standard error of 
the mean (SEM). N=3 
 
 
5.2.3 – Knockdown of FN1, ITGB1, and SLUG decreases CTC migration  
 
 Having demonstrated CTCs to be more migratory, and FN1, ITGB1 and SLUG to be 
upregulated in CTCs, we wanted to confirm whether this observed correlation was a direct cause 
and effect. To investigate the specific role of FN1, ITGB1, and SLUG in CTC migration, we 
performed transient knockdowns of each of these molecules in CTCs. As shown in Figure 5.3 A-
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B, knockdown of FN1, ITGB1, or SLUG caused a significant decrease in migration in comparison 
to scramble negative control. CBOH4 cells exhibited a 36% decrease in migration when FN1 was 
knocked down, followed by a 27% and 28% decrease when ITGB1 and SLUG were knocked 
down, respectively. Similarly, CBOH9 cell migration was lowered by 31% when FN1 was 
knocked down, followed by 43% and 37% decreases upon ITGB1 and SLUG knockdown. SLUG 
knockdown in the C22OH CRPC CTC line was unsuccessful for reasons yet to be determined. 
However, as shown in Figure 5.3 C, migration was reduced by 39% and 35% when either FN1 and 
ITGB1 were knocked down, respectively.  
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 Figure 5.3: CTCs demonstrate significantly decreased migration upon knockdown of 
 FN1, ITGB1, and SLUG. For HCC cells, wounds were made in a confluent plate of cells 
 and transient transfections were performed to determine FN1, ITGB1, and SLUG’s effect 
 on migration. A final concentration of 25pmol of appropriate siRNA, was used for 12 hours 
 until wounds closed for one condition. A) Effect of FN1, ITGB1, and SLUG knockdown 
 on CBOH4 migration. B) Effect of FN1, ITGB1, and SLUG knockdown on CBOH9 
 migration. For CRPC cells, 50,000 cells were placed in a transwell chamber containing 
 serum-free media. A final concentration of 25pmol of appropriate siRNA was used to 
 knockdown FN1 and ITGB1 to determine their corresponding role in migrating 
 through the transwell membrane (containing 8um pores) to the other side containing media 
 with serum. Transient transfections in transwell migration assay was carried out for 24 
 hours. C) Effect of FN1 and ITGB1 knockdown on C22OH migration. All migration 
 experiments were carried out 3 times. P values < 0.05 were deemed to be significant and 
 represented by *.  
 
 To determine whether simultaneously knocking down two or more of FN1, ITGB1, and 
SLUG will have a greater effect on migration than knocking down any of these molecules 
individually, we performed transient double and triple knockdowns. We compared them to the 
effects of individual single knockdowns of FN1, ITGB1, or SLUG on CTC migration. In all three 
CTC lines studied, we observed no additional increased reduction in CTC migration from 
knocking down both FN1 and ITGB1, FN1 and SLUG, or ITGB1 and SLUG in comparison to 
single molecular knockdowns (see Figure 5.4 A-C). Likewise, knocking down all three molecules 
(FN1, ITGB1, and SLUG) revealed no further decrease in migration than observed from individual 




 Figure 5.4: CTCs demonstrate similar decrease in migration regardless of whether 
 single,  double, or triple knockdowns of FN1, ITGB1, or SLUG were performed. For 
 HCC cells, wounds were made in a confluent plate of cells  and single, double, and triple 
 transient transfections were performed to determine FN1, ITGB1, and SLUG’s combined 
 knockdown effect on migration. A final concentration of 25pmol for each siRNA, was used 
 for 12 hours until wounds closed for one condition. A) Combination of different 
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 knockdowns of FN1, ITGB1, and SLUG and their effects on CBOH4 migration. B) 
 Combination of different knockdowns of FN1, ITGB1, and SLUG  and their effects on 
 CBOH9 migration. For CRPC cells, 50,000 cells were placed in a transwell chamber 
 containing serum-free media. A final concentration of 25pmol of appropriate siRNA was 
 used to knockdown FN1 and ITGB1 in single, double, or triple combinations. 
 Migration of cells through the transwell membrane (containing 8um pores) was measured. 
 Transient transfections for all conditions were carried out for 24 hours. C) Combination of 
 different knockdowns of FN1 and ITGB1 and their effect on C22OH migration. 
 Experiments were carried out 3 times. P< 0.05 were deemed to be significant. For all 
 graphs, blue bars represent single knockdowns, purple represents double knockdowns, and 
 the orange bar  represents triple knockdown.  
 
 
5.2.4 – FN1’s regulation of ITGB1 and SLUG are two separate pathways 
 
 Having reported FN1 to regulate both ITGB1 and SLUG, we wished to investigate whether 
ITGB1 and SLUG work in the same FN1 pathway. To ascertain whether ITGB1 may be upstream 
of SLUG, we transiently knocked down ITGB1 and looked at resulting effects on SLUG 
expression. As seen in Figure 5.5 A-C, SLUG expression did not change when ITGB1 was 
knocked down in all three CTC lines. Our results, therefore, appear to suggest that ITGB1 may not 
be regulating SLUG.  
 
 Figure 5.5: ITGB1 does not regulate SLUG expression in CTCs. When 75% confluent, 
 cells were transfected with a final concentration of 25pmol of siITGB1 for 24 hrs. Cells 
 were harvested and whole cell lysates used. Western blot analysis of SLUG protein 
 expression after ITGB1 is transiently knocked down in A) CBOH4, B) CBOH9 and C) 
 C22OH. Alpha-tubulin was used as a protein loading control. Experiments were carried 
 out 3 times.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
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 We also wished to investigate whether SLUG may potentially regulate ITGB1 expression. 
As shown in Figure 5.6 A-B, knocking down SLUG expression did not appear to affect ITGB1 
protein expression in either CBOH4 or CBOH9 CTCs. These data suggest that SLUG may not be 
upstream of ITGB1 in CTCs. Therefore, SLUG and ITGB1 may be two separate and possibly 
independent mechanisms by which FN1 may enhance CTC migration.  
 
 
 Figure 5.6: SLUG does not regulate ITGB1 expression in CTCs. When 75% confluent, 
 cells were transfected with a final concentration of 25pmol of siSLUG for 24 hrs. Cells 
 were harvested and whole cell lysates used. Western blot analysis of ITGB1 protein 
 expression after SLUG is transiently knocked down in A) CBOH4 and B) CBOH9. Protein 
 expression of alpha-tubulin was used as a protein loading control. Experiments were 
 performed 3 times.  
 
5.2.5 – FN1’s induction of CTC migration requires ITGB1 and SLUG expression 
 
 To further elucidate the mechanisms by which FN1 regulates CTC migration, we 
investigated the effects of adding recombinant FN1 to CTCs, concurrently transfected with either 
negative control scramble siRNA or ITGB1 siRNA. As shown in Figure 5.7 A, the addition of 
FN1 significantly increased migration of CBOH4 CTCs by 43%. However, when CBOH4 that 
previously demonstrated a 27% decrease in migration upon siITGB1 transfection were 
subsequently exposed to FN1, the addition of FN1 was unable to induce a very strong increase in 
CBOH4 CTC migration.  
 Similarly in Figure 5.7 B, we show that the addition of FN1 significantly induces migration 
by 64% in CBOH9. However, the subsequent addition of FN1 to CBOH9 (previously transfected 
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with siITGB1 and demonstrating a 39% decrease in migration), was unable to fully elevate 
migration levels of CBOH9. 
 Finally, in C22OH, the addition of FN1 also significantly induced migration by 30%, but 
was unable to induce migration prominently in C22OH with a previous knockdown of ITGB1. 
C22OH cells transfected with siITGB1 exhibited a significant decrease in migration by 22% that 
was unable to be salvaged completely by exposure of C22OH CTCs to FN1. This is seen in Figure 
5.7 C. From these results, we can conclude that FN1’s induction of migration requires the presence 




 Figure 5.7: FN1’s induction of migration by CTCs requires ITGB1. Recombinant FN1 
 was added to CTCs (at a final dose of 2ug/ml) that were treated concurrently with either 
 siScramble or siITGB1 (25pmol final concentration). Migration was then assessed using 
 wound healing assays  performed on A) CBOH4 and B) CBOH9. Wound healing assays 
 were stopped within 10-12 hrs when the wounds for one condition of treated cells closed. 
 Transwell migration assay was performed on C) C22OH using 2ug/ml of recombinant FN1 
 and a final concentration of 25pmol of either siScramble or siITGB1. Transwell migration 
 through 8um pore containing membranes was measured and stopped at 24hrs. Data 
 provided on graphs are presented as mean ± standard error of the mean (SEM); N=3; *P < 
 0.05; **P < 0.01. 
 
 Having demonstrated that FN1’s induction of CTC migration requires ITGB1, we were 
curious to see whether SLUG expression was also necessary for FN1’s ability to induce migration. 
To determine whether FN1 requires SLUG, we evaluated the effect of treating CTCs with siSLUG 
followed by the addition of FN1. As shown in Figure 5.8 A, FN1 is unable to completely induce 
migration of CBOH4 CTCs that had previously been subjected to ITGB1 knockdown. Similar 
results are demonstrated in Figure 5.8 B. FN1 is unable to efficiently enhance migration of CBOH9 
CTCs with previous SLUG knockdown. These finding indicate that FN1’s significant induction of 




 Figure 5.8: FN1’s induction of migration by CTCs requires SLUG expression. 
 Recombinant FN1 was added to CTCs (at a final dose of 2ug/ml) that were treated 
 concurrently with either siScramble or siSLUG (25pmol final concentration). Migration 
 was then assessed using wound healing assays performed on A) CBOH4 and B) CBOH9. 
 Wound healing assays were stopped within 10-12 hrs when the wounds for one condition 
 of treated cells closed. Data are presented as mean ± standard error of the mean (SEM); 




 FN1 is a matrix glycoprotein with a number of roles in human health and disease, including 
embryonic development, tissue regeneration, cell growth, cell migration, and tumorigenesis [127, 
128]. FN1’s ability to carry out its many functions depends on the various molecules it interacts 
with, including integrin transmembrane cell receptors and the ECM [128-130]. Interestingly, 
upregulation of FN1 has been observed in a variety of cancers [53, 143]. Consequently, a better 
understanding of how FN1 promotes tumorigenesis could have beneficial clinical implications in 
multiple cancers.  
 While a number of studies highlight FN1’s overexpression in tumor tissue [128], our 
current study has focused on elucidating novel molecular mechanisms by which FN1 can promote 
cell migration, a critical aspect of the metastatic cascade [9]. We were particularly interested in 
studying the role of elevated FN1 expression in CTCs. The objective of our study was to determine 
how FN1 may enhance CTC migration and therefore contribute to metastasis. We previously 
observed that in comparison to primary tumor cells, CTCs were more migratory and expressed 
greater levels of FN1, as well as ITGB1 and SLUG. We now demonstrate the substantial 
contributions of each of these molecules to CTC migration. Single knockdowns of FN1, ITGB1, 
and SLUG significantly lowered migration by as much as 43% in some cases, indicating their 
requirement for CTC migration. It is noteworthy to point out that double knockdown of FN1 and 
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ITGB1, FN1 and SLUG, or ITGB1 and SLUG, as well as triple knockdown of FN1, ITGB1, and 
SLUG did not further inhibit CTC migration in comparison to single knockdowns. This suggests 
a direct role of these three molecules in CTC migration.  
 Having shown all three to be critical in the promotion of CTC migration, we investigated 
whether there existed any relationship among FN1, ITGB1, and SLUG.  While FN1 binding and 
activation of integrin receptors has been long established [112, 144], we report for the first time 
the observation that FN1 can also regulate ITGB1 expression. FN1 knockdown in CTCs resulted 
in a corresponding decrease in ITGB1 protein expression. It should be noted however that a 
potential question unanswered by our work is how FN1 may be regulating ITGB1 transcription or 
through stabilization of ITGB1 protein. The western blot approach we used tells us only that 
ITGB1 protein expression is decreased upon FN1 knockdown. It will be important to examine 
ITGB1 mRNA expression, as this may further clarify how FN1 may regulate ITGB1 to promote 
enhanced CTC migration.  
 Similarly, we also investigated FN1’s ability to regulate SLUG. Interestingly we observed 
that FN1 knockdown also significantly downregulated SLUG mRNA expression in CTCs. While 
FN1 has previously been reported to regulate SLUG in renal cell carcinoma cells for the promotion 
of metastasis by Knowles et al [59], we are the first to report this finding in CTCs. These 
observations give further support to the importance of studying mechanisms of CTC migration to 
further understand metastasis promoting mechanisms. 
 Establishing FN1’s regulation of ITGB1 and SLUG, we next wanted to determine whether 
FN1’s regulation of both molecules existed via the same or 2 distinct pathways. To achieve this 
goal, we first knocked down ITGB1 to assess potential changes in SLUG protein expression via 
Western blot. Previous work suggest that this is plausible. Desgrosellier et al [145], for example, 
showed integrin B3 to drive SLUG activation in neoplastic mammary gland. Furthermore, one of 
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the downstream pathways of ITGB1 is TGFB1 [130, 146], which has been reported to be upstream 
of SLUG [147]. Therefore, it is conceivable that FN1 may regulate ITGB1 resulting in TGFB1-
mediated regulation of SLUG. However, upon knocking down ITGB1, we observed no change in 
SLUG protein expression. Notwithstanding, it is still plausible that while no change in SLUG 
protein expression was observed, SLUG may be regulated at transcriptional level by FN1 
regulation of ITGB1. Also, SLUG is a transcription factor that is often shuttled to the nucleus by 
importins to perform its activity but can also be found in the cytoplasm as well [148]. Further 
follow-up studies may entail using either immunofluorescence or cell fractionation to definitively 
assess the possibility of ITGB1 regulating SLUG expression during CTC migration.   
 Conversely, we explored SLUG regulation of ITGB1 by assessing ITGB1 expression when 
SLUG is knocked down. We wanted to test the possibility that perhaps SLUG is upstream of 
ITGB1. SLUG has in fact been reported to be upstream of integrin receptors in keratinocytes [149] 
and a metastatic subpopulation of ovarian cancer cells [150]. However, upon SLUG knockdown, 
we observed no change in ITGB1 protein expression and therefore our data seems to suggest that 
SLUG may not regulate ITGB1. Consequently, we believe FN1’s regulation of ITGB1 and SLUG 
may be two separate and independent pathways by which FN1 induces CTC migration and 
promotes metastasis.  
 FN1’s regulation of ITGB1 and SLUG further evoked questions of whether these 
molecules were necessary for FN1 to exert its effects on migration. CTCs treated with recombinant 
FN1 exhibited a significant increase in CTC migration. However, when either ITGB1 or SLUG 
were knocked down, the addition of FN1 proved incapable of eliciting the same increase in 
migration. Knock down of ITGB1 or SLUG impaired FN1’s ability to enhance migration. We, 
therefore, concluded that these 2 molecules, ITGB1 and SLUG, are needed by FN1 to significantly 
increase CTC migration.  
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 These findings are noteworthy in that they contribute to our understanding of the role of 
FN1 in cancer metastasis by highlighting 2 new mechanisms that enhance CTC migration. 
Previous studies have focused on FN1’s intriguing overexpression in tumor tissue and its 
correlation with a poorer prognosis [125, 126, 151-153]. The current data provides some 
explanation as to the molecules FN1 actively regulates to significantly increase CTC migration 
and consequently metastatic spread. To date, FN1 research in CTCs has been limited to its 
overexpression indicating EMT [77, 139-141] or CTCs benefiting from stromal FN1 produced by 
neighboring cells [154]. However, we are now showing that increased expression of FN1 by CTCs 
plays a fundamental role in enhancing CTC migration, which is essential for metastasis.  
 Our proposed model is illustrated in Figure 5.9. Our findings suggest that FN1 expression 
within CTCs is important for their enhanced migration. Furthermore, we propose that FN1’s 
regulation of ITGB1 and SLUG may occur through two separate and possibly independent 
pathways. Future work will focus on clarifying this proposed mechanism, and on further 
investigation of the exact molecules downstream of FN1’s regulation of ITGB1 and SLUG that 
enable CTC migration. 
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Figure 5.9: Proposed model of how increased intracellular FN1 expression in CTCs 
contributes to their enhanced migration. It has previously been observed that increased FN1 
expression in tumors has been correlated with poorer patient survival. Interestingly, CTCs 
demonstrate significantly increased FN1expression in comparison to primary tumor cells. We now 
show that FN1 regulates ITGB1 and SLUG through two seemingly separate and independent 
pathways. Furthermore, our data suggests that both ITGB1 and SLUG are necessary for FN1-



























































 Metastasis is defined as the spread of cancer from one part of the body to another. 
Responsible for over 90% of cancer mortalities every year, metastasis remains a big problem for 
which there is currently no cure. It involves a number of steps. From a cell’s dissociation from the 
primary tumor, to its migration through tissues, intravasation into the blood, eventual extravasation 
and secondary site colonization, there are many aspects of metastasis that are still not fully 
understood [2, 3, 5]. 
 A non-invasive way we have sought to investigate molecular mechanisms leading to 
metastasis is through the use of CTCs. These cells are a critical part of the metastatic cascade. 
Although their counts within the blood are low, these are the cells that will eventually form 
secondary metastatic lesions [10, 11, 13]. In order to circumvent their low numbers, we have 
isolated CTCs and established them into long-term cell lines. We have taken advantage of two 
different mice models: a syngeneic mice model of HCC and a xenograft mice model of CRPC. 
Both HCC and CRPC were chosen as the cancers for this study because they both result in eventual 
and frequent metastasis and are in need of better treatment options [39, 43, 46, 47, 131]. We are 
among the select few who have been successful at creating long-term CTC lines [24-27]. In 
addition, we have also made corresponding primary tumor cell lines with which to compare our 
CTCs with. Our goal was to functionally and molecularly characterize the three CTC lines and 
observe similarities across different tissue origins. We hypothesized that there may be certain 
things all CTCs share in terms of intrinsic biological mechanisms, regardless of what kind of 
cancer they originate from. 
 For our experiments, we decided to focus on 2 major hallmarks of cancer: migration 
mechanisms promoting metastasis and evasion of the immune system [52]. Taking advantage of 
our syngeneic mouse model of HCC and that this model has an intact immune system [48], we 
found that CTCs displayed a downregulation in MHCI cell surface expression. While this is a well-
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established mechanism by which tumor cells can escape immune detection [85], we are among the 
first to assess MHCI expression in newly established CTC lines. Furthermore, we identified three 
cytokines secreted in lower amounts by CTCs: endostatin, CXCL5, and proliferin. While only 
CXCL5 has a direct role in recruiting neutrophils and in this way holds intrinsic 
immunomodulatory properties [92, 93, 104], endostatin seems to enhance the effect of several 
immunotherapies by a presently unknown mechanism [113, 114]. As such, endostatin may still 
hold important immunomodulatory implications and cannot be ruled out. Further investigation of 
endostatin, proliferin, and CXCL5 in CTCs is needed. Surprisingly, all three of these differentially 
secreted molecules have either anti- or pro- angiogenic roles [58, 96, 118-120].  Consequently, it 
would be interesting to determine whether lower secretion of these molecules in CTCs has any 
effect on its angiogenic behavior and what implications this may have on their ability to colonize 
secondary sites and further promote metastasis. 
 Moreover, our CTC lines shared common characteristics despite originating from different 
tissues. Interestingly, all CTCs demonstrated greater migration than their corresponding primary 
tumor cell lines. Not surprisingly, CTCs demonstrated EMT, as shown by decreased E-cadherin 
and increased FN1 and SLUG expression. Furthermore, ITGB1 was also found to be upregulated 
in all CTCs.  
 Following up on these observations, we were intrigued that FN1, SLUG, and ITGB1 all 
have known roles in cell migration [56, 57, 134, 136-138, 153, 155]. The fact that CTCs 
demonstrated enhanced migration elicited curiosity as to whether this correlation was a direct 
cause and effect of increased expression of any or all of these three molecules. We demonstrate all 
three to have a direct role in enhancing CTC migration. We also show for the first time that FN1 
regulates ITGB1 and SLUG, and that FN1’s regulation of both molecules seem to occur via 2 
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separate and independent pathways. In addition, we reveal that FN1 requires both ITGB1 and 
SLUG to significantly increase CTC migration.   
 The significance of our work lies in that we are the first to report a novel regulatory role of 
FN1 in CTCs. While most research on FN1 has focused on its critical role in the ECM and 
connecting cells with their ECM exterior [123, 124, 130], we have focused on uncovering FN1’s 
direct regulation of specific molecules in order to enhance CTC migration. Migration is a necessary 
criteria and hallmark of cancer that is needed for metastasis to occur [9]. Our work has implications 
for CTCs producing increased levels of FN1 and this consequently affecting CTC migration. 
 Future directions include further investigation of endostatin, CXCL5, and proliferin. We 
are interested in uncovering what potential roles they play and whether lower secretions confer a 
metastatic advantage or have a direct regulatory role on CTC behavior. Having observed lower 
MHCI expression, we were also interested in investigating the implications on CTCs’ ability to 
evade recognition by CTLs via in-vivo mouse studies or co-cultures.  Finally, it is interesting that 
endostatin, CXCL5, and proliferin all have previously reported roles in regulating angiogenesis 
[96, 118-120]. It is presently unknown whether CTCs are angiogenic or not and how this may aid 
in the dissemination of cancer cells and their subsequent spread throughout the body. 
 It is important to point out that while we have been able to delineate 2 novel pathways by 
which FN1 can enhance migration, we have not pinpointed what lies downstream of either ITGB1 
or SLUG. Preliminary investigations demonstrate Rac1, RhoA, and ERK/P-ERK to remain 
unchanged when FN1, ITGB1, and SLUG are knocked down. These molecules were specifically 
investigated because of their well established roles in migration and their known roles as 
downstream effectors of integrin receptors [130]. However, there remains a number of alternative 
signaling molecules involved in migration that have not been looked into, such as PI3K, AKT, 
talin, cMet, or other cytoskeletal proteins [9, 156]. Future studies should investigate these other 
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potential downstream targets. Further, it is also not fully clear whether intracellular FN1 or FN1 
secretion acting in an autonomous fashion is what is driving enhanced CTC migration. Further 
experiments investigating this could include testing the possibility that secreted FN1 works 
autonomous on ITGB1 receptors to induce enhanced CTC migration. In this regard, one could take 
media from CTCs which could be rich in secreted FN1 and expose that to primary tumor cells to 
see if this is enough to elevate ITGB1 and SLUG expression and consequently promote CTC 
migration. These future experiments could shed greater light on the exciting and promising new 
molecular pathways regulated by FN1 that were discovered and discussed in this thesis. 
 In conclusion, our study has revealed possibilities for ways CTCs may evade immune 
detection, as well as novel molecular mechanisms of CTC migration. Because CTC migration is a 
critical aspect of metastatic dissemination, these mechanisms may have important implications for 
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